InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (8 ops.)
Insider track record
CFODisclosed buys
1
Disclosed sells
8
T+90 hit rate
60%
T+90 mean return
-0.6%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Moran Kevin Patrick, Chief Financial Officer. Insider active across 1 company, notably Vanda Pharmaceuticals Inc.. Cumulatively, 15 reports have been recorded. Split: 1 buy · 8 sells. Total volume traded: €279k. History available since 28 July 2021. The latest transaction was filed on 1 March 2025 (Retenue fiscale). Regulator: SEC (Form 4). The full history is openly available.
Declarations15 total
26,941 shares@ US$4.7629.1% of flowCommon StockSEC:0000950170-25-032273:0
2,000 shares@ US$4.38942.0% of flowCommon StockSEC:0000950170-25-025914:0
Ideal exit: 18 Nov 2025 (T+270)
125,000 shares0Common StockSEC:0000950170-25-024487:0
2,251 shares@ US$5.92032.9% of flowCommon StockSEC:0000950170-24-087381:0
5,798 shares@ US$4.48125.6% of flowCommon StockSEC:0000950170-24-027253:0
125,000 shares0Common StockSEC:0000950170-24-018027:0
412 shares@ US$6.300.6% of flowCommon StockSEC:0001209191-23-043990:0
16,000 shares@ US$6.294421.7% of flowCommon StockSEC:0001209191-23-038417:0
7,966 shares@ US$6.257311.0% of flowCommon StockSEC:0001209191-23-016461:0
32,700 shares0Common StockSEC:0001209191-23-011340:0
7,500 shares@ US$3.125.2% of flowCommon StockSEC:0001209191-22-060225:0
2,239 shares@ US$10.975.7% of flowCommon StockSEC:0001209191-22-043682:0
32,700 shares0Common StockSEC:0001209191-22-015155:0
2,130 shares@ US$19.23618.1% of flowCommon StockSEC:0001209191-21-048738
2,130 shares@ US$19.23610.0092% mcap50.0% of flowCommon StockSEC:0001209191-21-048738:0
15 of 15 declarations
About Moran Kevin Patrick
Kevin Patrick Moran is the Chief Financial Officer, Senior Vice President, and Treasurer at Vanda Pharmaceuticals Inc. He oversees the company's financial operations, including financial planning, risk management, and financial reporting. His expertise is essential for ensuring the financial health of the company and supporting its growth strategy.
